Stryker Corporation (SYK)

$390.14

+4.46

(+1.16%)▲

Market is closed - opens 8 PM, 22 Nov 2024
star icon

Stryker Corporation is a medical technology company that develops and manufactures innovative products for orthopedics, spine, and neurotechnology.

Performance

  • $384.82
    $390.22
    $390.14
    downward going graph

    1.36%

    Downside

    Day's Volatility :1.38%

    Upside

    0.02%

    downward going graph
  • $285.79
    $398.20
    $390.14
    downward going graph

    26.75%

    Downside

    52 Weeks Volatility :28.23%

    Upside

    2.02%

    downward going graph

Returns

PeriodStryker CorporationSector (Health Care)S&P500
3 Months
11.24%
-6.9%
6.8%
6 Months
16.31%
-1.7%
12.1%
1 Year
32.68%
10.4%
30.6%
3 Years
49.88%
8.8%
27.0%

Highlights

Market Capitalization
147.0B
Book Value
$52.86
Dividend Share
3.2
Dividend Yield
0.83%
Earnings Per Share (EPS)
9.33
PE Ratio
41.34
PEG Ratio
2.69
Wall Street Target Price
395.883
Profit Margin
16.34%
Operating Margin TTM
21.59%
Return On Assets TTM
7.11%
Return On Equity TTM
18.87%
Revenue TTM
22.0B
Revenue Per Share TTM
57.73
Quarterly Revenue Growth YOY
11.899999999999999%
Gross Profit TTM
11.6B
EBITDA
5.7B
Diluted Eps TTM
9.33
Quarterly Earnings Growth YOY
0.2
EPS Estimate Current Year
12.05
EPS Estimate Next Year
13.5
EPS Estimate Current Quarter
2.77
EPS Estimate Next Quarter
3.92

Analyst Recommendation

Buy
    67%Buy
    32%Hold
    0
    0%Sell
Based on 34 Wall street analysts offering stock ratings for Stryker Corporation(by analysts ranked 0 to 5 stars)
Based on 34 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
23
23
22
Hold
11
11
11
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1.47%

Current $390.14
Target $395.88

Company Financials

FY18Y/Y Change
Revenue
13.6B
↑ 9.3%
Net Income
3.6B
↑ 248.33%
Net Profit Margin
26.12%
↑ 17.92%
FY19Y/Y Change
Revenue
14.9B
↑ 9.43%
Net Income
2.1B
↓ 41.37%
Net Profit Margin
13.99%
↓ 12.13%
FY20Y/Y Change
Revenue
14.4B
↓ 3.58%
Net Income
1.6B
↓ 23.24%
Net Profit Margin
11.14%
↓ 2.85%
FY21Y/Y Change
Revenue
17.1B
↑ 19.21%
Net Income
2.0B
↑ 24.7%
Net Profit Margin
11.66%
↑ 0.52%
FY22Y/Y Change
Revenue
18.4B
↑ 7.84%
Net Income
2.4B
↑ 18.25%
Net Profit Margin
12.78%
↑ 1.12%
FY23Y/Y Change
Revenue
20.5B
↑ 11.11%
Net Income
3.2B
↑ 34.22%
Net Profit Margin
15.44%
↑ 2.66%
Q2 FY23Q/Q Change
Revenue
5.0B
↑ 4.56%
Net Income
738.0M
↑ 24.66%
Net Profit Margin
14.77%
↑ 2.38%
Q3 FY23Q/Q Change
Revenue
4.9B
↓ 1.74%
Net Income
692.0M
↓ 6.23%
Net Profit Margin
14.1%
↓ 0.67%
Q4 FY23Q/Q Change
Revenue
5.8B
↑ 18.46%
Net Income
1.1B
↑ 65.17%
Net Profit Margin
19.66%
↑ 5.56%
Q1 FY24Q/Q Change
Revenue
5.2B
↓ 9.84%
Net Income
788.0M
↓ 31.06%
Net Profit Margin
15.03%
↓ 4.63%
Q2 FY24Q/Q Change
Revenue
5.4B
↑ 3.41%
Net Income
825.0M
↑ 4.7%
Net Profit Margin
15.22%
↑ 0.19%
Q3 FY24Q/Q Change
Revenue
5.5B
↑ 1.33%
Net Income
834.0M
↑ 1.09%
Net Profit Margin
15.18%
↓ 0.04%
FY18Y/Y Change
Total Assets
27.2B
↑ 22.75%
Total Liabilities
15.5B
↑ 27.16%
FY19Y/Y Change
Total Assets
30.2B
↑ 10.79%
Total Liabilities
17.4B
↑ 12.01%
FY20Y/Y Change
Total Assets
34.3B
↑ 13.8%
Total Liabilities
21.2B
↑ 22.38%
FY21Y/Y Change
Total Assets
34.6B
↑ 0.88%
Total Liabilities
19.8B
↓ 7.02%
FY22Y/Y Change
Total Assets
36.9B
↑ 6.51%
Total Liabilities
20.3B
↑ 2.6%
FY23Y/Y Change
Total Assets
39.9B
↑ 8.21%
Total Liabilities
21.3B
↑ 5.19%
Q2 FY23Q/Q Change
Total Assets
37.4B
↑ 1.57%
Total Liabilities
20.0B
↑ 0.57%
Q3 FY23Q/Q Change
Total Assets
38.0B
↑ 1.69%
Total Liabilities
20.1B
↑ 0.44%
Q4 FY23Q/Q Change
Total Assets
39.9B
↑ 4.92%
Total Liabilities
21.3B
↑ 5.87%
Q1 FY24Q/Q Change
Total Assets
39.4B
↓ 1.28%
Total Liabilities
20.2B
↓ 5.11%
Q2 FY24Q/Q Change
Total Assets
39.1B
↓ 0.69%
Total Liabilities
19.4B
↓ 4.26%
Q3 FY24Q/Q Change
Total Assets
43.8B
↑ 12.02%
Total Liabilities
23.7B
↑ 22.28%
FY18Y/Y Change
Operating Cash Flow
2.6B
↑ 67.42%
Investing Cash Flow
-2.9B
↑ 77.12%
Financing Cash Flow
1.3B
↓ 267.38%
FY19Y/Y Change
Operating Cash Flow
2.2B
↓ 16.05%
Investing Cash Flow
-1.5B
↓ 49.07%
Financing Cash Flow
3.0M
↓ 99.77%
FY20Y/Y Change
Operating Cash Flow
3.3B
↑ 49.57%
Investing Cash Flow
-4.7B
↑ 223.09%
Financing Cash Flow
-11.0M
↓ 466.67%
FY21Y/Y Change
Operating Cash Flow
3.3B
↓ 0.43%
Investing Cash Flow
-859.0M
↓ 81.73%
Financing Cash Flow
-2.4B
↑ 21400.0%
FY22Y/Y Change
Operating Cash Flow
2.6B
↓ 19.58%
Investing Cash Flow
-2.9B
↑ 240.4%
Financing Cash Flow
-749.0M
↓ 68.33%
Q2 FY23Q/Q Change
Operating Cash Flow
688.0M
↑ 54.61%
Investing Cash Flow
-533.0M
↑ 303.79%
Financing Cash Flow
-405.0M
↓ 15.8%
Q3 FY23Q/Q Change
Operating Cash Flow
1.1B
↑ 52.62%
Investing Cash Flow
-810.0M
↑ 51.97%
Financing Cash Flow
-422.0M
↑ 4.2%

Technicals Summary

Sell

Neutral

Buy

Stryker Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Stryker Corporation
Stryker Corporation
5.37%
16.31%
32.68%
49.88%
93.53%
Boston Scientific Corp.
Boston Scientific Corp.
3.97%
21.4%
65.07%
124.82%
118.64%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
1.65%
-21.98%
4.95%
-38.71%
-12.32%
Abbott Laboratories
Abbott Laboratories
0.98%
11.87%
14.18%
-6.39%
40.03%
Medtronic Plc
Medtronic Plc
-7.0%
-1.19%
8.13%
-27.5%
-23.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Stryker Corporation
Stryker Corporation
41.34
41.34
2.69
12.05
0.19
0.07
0.01
52.86
Boston Scientific Corp.
Boston Scientific Corp.
74.52
74.52
1.64
2.46
0.09
0.05
NA
14.05
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.17
27.17
6.38
2.53
0.19
0.11
NA
16.18
Abbott Laboratories
Abbott Laboratories
35.56
35.56
2.25
4.68
0.15
0.06
0.02
22.94
Medtronic Plc
Medtronic Plc
29.55
29.55
1.63
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Stryker Corporation
Stryker Corporation
Buy
$147.0B
93.53%
41.34
16.34%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$132.9B
118.64%
74.52
11.26%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$41.5B
-12.32%
27.17
65.86%
Abbott Laboratories
Abbott Laboratories
Buy
$203.2B
40.03%
35.56
13.99%
Medtronic Plc
Medtronic Plc
Buy
$110.3B
-23.53%
29.55
12.06%

Insights on Stryker Corporation

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 5.24B → 5.49B (in $), with an average increase of 2.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 788.0M → 834.0M (in $), with an average increase of 2.8% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 65.1% return, outperforming this stock by 32.4%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 124.8% return, outperforming this stock by 74.9%

Institutional Holdings

  • Vanguard Group Inc

    8.51%

  • BlackRock Inc

    7.03%

  • Greenleaf Trust

    4.86%

  • State Street Corp

    3.74%

  • T. Rowe Price Associates, Inc.

    3.07%

  • Wellington Management Company LLP

    2.95%

Corporate Announcements

  • Stryker Corporation Dividends March,2024

    In the quarter ending March,2024. Stryker Corporation has declared dividend of $0.80

    Read More

Company Information

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan.

Organization
Stryker Corporation
Employees
52000
CEO
Mr. Kevin A. Lobo
Industry
Health Technology

FAQs